Shiseido has signed a binding agreement to sell its Chinese subsidiary, Shiseido Liyuan Cosmetics (SLC), to an investor consortium led by Hong Kong-based private equity firm IDG Capital. SLC makes and sells the Aupres brand in China. Financial terms were not disclosed.
The transaction is expected to close between the fourth quarter of 2026 and the first quarter of 2027, subject to regulatory approvals, including in China. Under the deal, funds managed by IDG Capital will take 95% of the equity through two special purpose vehicles. A limited partnership enterprise set up mainly by SLC's new management team will hold the remaining 5%.
Divestment tied to 2030 strategy
Shiseido said the sale is part of its effort to improve profitability and capital efficiency under its 2030 Medium-Term Strategy. The group wants to focus management resources on areas where it enjoys the greatest competitive advantage, and to concentrate on priority brands and higher-growth opportunities.
According to Shiseido, SLC requires continued investment in product innovation and digital capabilities. The divestment sheds that requirement from the group while keeping China as a strategically important market. Shiseido described China as attractive and dynamic, with a competitive landscape changing amid e-commerce expansion, shifting consumer behavior and the emergence of diverse market participants.
Joint venture background
SLC was established in 1991 as a joint venture with Beijing Liyuan, a subsidiary of Yiqing Group, which is owned by the Beijing Municipal Government. SLC has sold the C-beauty brand Aupres since 1994.
With the joint venture agreement set to expire in December 2026, the parties agreed not to renew it. On September 1, 2026, Shiseido acquired Beijing Liyuan's 35% stake, giving it full ownership ahead of the sale.
Handover and continued support
The deal includes SLC's Beijing factory and production equipment. Shiseido said it believes independent operation under IDG will support SLC's sustainable growth and brand value.
To ensure a smooth handover, Shiseido will license the intellectual property rights IDG needs to run the business. For a specified period after the transfer, Shiseido will also provide support on new product development, technical assistance for the stable supply of existing products, and continued supply of raw materials and selected products. The company said the arrangements are intended to maintain SLC's innovation capabilities, product quality and business continuity.
Profit recovery context
The divestment comes days after Shiseido reported a 124.3% jump in core operating profit for the third quarter of 2026, to ¥67.5 billion (US$422.13 million). The company attributed the recovery to restructuring, cost cuts and improved margins rather than strong product demand; like-for-like sales grew 0.7%.
Shiseido raised its full-year core operating profit forecast from ¥59 billion (US$433 million) to ¥87 billion (US$546 million) on the back of those results.
